Related Experiment Video

Updated: Jul 14, 2026

In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

Increased thrombogenesity in patients with cyanotic congenital heart disease

Hidemi Kajimoto1, Makoto Nakazawa, Kagari Murasaki

  • 1Department of Pediatric Cardiology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan.

Circulation Journal : Official Journal of the Japanese Circulation Society
|May 29, 2007
PubMed

Insights

Platelet activation is present in cyanotic congenital heart disease (CCHD) patients, indicated by elevated P-selectin. This platelet activation may contribute to thromboembolic events in CCHD.

Area of Science:

  • Cardiology
  • Hematology
  • Thrombosis Research

Background:

  • Mechanisms of thromboembolism in cyanotic congenital heart disease (CCHD) remain unclear.
  • P-selectin indicates platelet activation; thrombomodulin reflects endothelial anticoagulant activity.
  • This study investigates platelet activation in CCHD patients.

Purpose of the Study:

  • To evaluate the presence and extent of platelet activation in patients with CCHD.
  • To assess markers of endothelial anticoagulant activity in CCHD.
  • To explore the relationship between platelet activation and thromboembolic events in CCHD.

Main Methods:

  • Examined P-selectin (platelet activation marker), plasma thrombomodulin, protein C activity (endothelial markers), and thrombin-antithrombin complex III (TAT) in 35 CCHD patients and controls.
  • Measured P-selectin on platelets and plasma levels of thrombomodulin, protein C, and TAT.
  • Compared marker levels between CCHD patients and healthy controls.

Main Results:

  • CCHD patients showed significantly lower plasma thrombomodulin and protein C activity compared to controls.
  • Levels of plasma TAT and platelet P-selectin were significantly higher in CCHD patients.
  • Elevated platelet P-selectin was observed in CCHD patients who experienced thromboembolic events (p=0.02).

Conclusions:

  • Platelet activation is evident in patients with CCHD.
  • This platelet activation may play a significant role in the occurrence of thromboembolic events in CCHD.
  • Findings suggest potential therapeutic targets for preventing thromboembolism in CCHD.
Abstract

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...